Similarly, specific adverse events typically associated with VEGF inhibition, such as hypertension, bleeding, or thromboembolic events, did not occur more frequently in the study described here than in monotherapy studies of other VEGF inhibitors (Herbst et al, 2005) or in gemcitabine combination studies, such as a phase 2 trial of bevacizumab plus gemcitabine in advanced pancreatic cancer (Kindler et al, 2005). The gene discussed is VEGFA; the disease is Hypertension.